Every material Form 8-K NEUROONE MEDICAL TECHNOLOGIES Corp has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
NeuroOne preliminarily reported fiscal fourth-quarter 2026 product revenue of approximately $3.8 million, up 38.4% from the prior-year quarter, and full-year revenue of approximately $10.5 million, up 15.6% and at the top of its guidance range. The company also disclosed a $4.5 million purchase order received in September 2026, which it describes as its largest ever, and open purchase orders of $5.4 million as of September 30, 2026. The figures are unaudited and subject to change, with final results due in December 2026.
Fiscal Q4 2026 product revenue of approximately $3.8 million, up 38.4% from approximately $2.7 million in Q4 2025.
Full-year fiscal 2026 revenue of approximately $10.5 million, up 15.6%, at the top of the previously announced $9.2 million to $10.5 million guidance range.
$4.5 million purchase order received in September 2026; about $1.0 million shipped by September 30, with the remaining $3.6 million expected to begin shipping in fiscal Q1 2027.
Open purchase orders totaled $5.4 million as of September 30, 2026; complete results are expected in December 2026 with the Form 10-K.
NeuroOne Medical Technologies announced that three large-animal procedures using its StereoCED platform were completed at the University of Minnesota as part of a preclinical epilepsy research program. The company says the procedures established technical feasibility, and it expects to recognize related animal-use revenue in fiscal Q4 2026 and plans a launch for human investigational studies later this quarter, though the filing gives no revenue amount and the platform is not approved for commercial use.
Three large-animal procedures completed at the University of Minnesota, announced August 27, 2026
In two of the three procedures, drug delivery electrodes delivered a study agent into targeted brain tissue and recorded electrophysiological activity from the same regions
Revenue from the animal-use devices is expected to be recognized in fiscal Q4 2026; no dollar amount is given
Human investigational device release is planned by the end of fiscal Q4 2026, with launch planned later this quarter
NeuroOne reported fiscal third-quarter 2026 results for the period ended June 30, 2026. Product revenue rose 16% year over year to $2.0 million and product gross margin reached 59.9%, but the net loss widened to $2.0 million from $1.5 million, and cash fell to $2.0 million from $6.6 million at September 30, 2025.
Product revenue was $2.0 million, up from $1.7 million in the year-ago quarter.
Net loss was $2.0 million, or $(0.23) per basic share, versus $1.5 million, or $(0.19) per basic share, a year earlier.
Product orders were $2.7 million in the quarter, and fiscal 2026 product orders to date total $11.2 million.
Cash and cash equivalents were $2.0 million as of June 30, 2026, and the company raised $8.4 million gross through its at-the-market program since the start of the fiscal year (through June 30, 2026).
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NEUROONE MEDICAL TECHNOLOGIES Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →